CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity

CordenPharma, a leading global Contract Development and Manufacturing Organization (CDMO), announces that it has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO.

Scaling CordenPharma's facility network

AmbioPharm employs approximately 400 people across its two sites. The acquisition builds on CordenPharma's global facility network of 11 sites in Europe and North America by expanding its U.S. peptide manufacturing capacity and bringing Shanghai-based peptide supply into its operational footprint.

Dr. Michael Quirmbach, President & CEO of CordenPharma Group, commented: "This acquisition significantly bolsters CordenPharma's Peptides Platform with complementary capabilities and advances our strategic objective to serve as a leading peptide manufacturing partner. As peptide programs become more complex and advanced, customers value CDMO partners who can offer both upstream scientific route selection and process robustness with downstream manufacturing scale and built-in geographic flexibility. AmbioPharm's capabilities perfectly complement our existing peptide expertise, helping us to broaden the ways we support customers from development to commercialization."

"Becoming part of CordenPharma marks an exciting new chapter for AmbioPharm. Together, we will be able to offer customers broader technical capabilities, increased global capacity, and a highly reliable Peptides Platform to support the development and commercialization of peptide-based medicines, delivered through a fully-integrated global facility network. Importantly, we remain focused on the patients who rely on these medicines," said AmbioPharm CEO Brian Gregg.

"This acquisition marks an important step in CordenPharma's growth journey, enhancing the company's strategic positioning and supporting significant long-term growth opportunities in peptides," said Astorg Director Antoine Thomas. CordenPharma's Chairman of the Board, Paul Perreault, commented, "This is an exciting time for the promise of peptides to help patients across the globe, and now at CordenPharma we strengthen our capabilities to deliver this promise for our partners."